Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-1484 Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
NCT05382325Phase 1Terminated
- Sponsor
- Merck & Co.
- Start
- Jun 2022
- Primary completion
- Sep 2026
- Modality
- Prophylactic Vaccines, Recombinant Proteins and Enzymes, Therapeutic Vaccines
- Countries
- 4
01
Overview
Phase 1, open-label trial of MK-1484 in solid tumor (2 arms), sponsored by Merck & Co. Primary endpoints: Dose-Limiting Toxicity at 21 days, Adverse Events at 27 months and 1 more. Started Jun 2022; status: terminated.
02
Drugs
MK-1484
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05382325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05382325.